OptiNose (NASDAQ:OPTN) released its quarterly earnings results on Monday. The company reported ($0.66) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.09, Bloomberg Earnings reports. The firm had revenue of $6.68 million for the quarter, compared to analysts’ expectations of $7.74 million. OptiNose had a negative net margin of 983.22% and a negative return on equity of 81.04%.
OptiNose stock opened at $6.26 on Wednesday. The firm has a 50-day moving average of $6.30. OptiNose has a twelve month low of $4.44 and a twelve month high of $19.92. The company has a market cap of $258.31 million, a PE ratio of -2.34 and a beta of 0.90. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.74 and a current ratio of 6.95.
Several research firms have weighed in on OPTN. ValuEngine raised shares of OptiNose from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Piper Jaffray Companies set a $29.00 price target on shares of OptiNose and gave the company a “buy” rating in a report on Tuesday, April 23rd. BMO Capital Markets lowered their price target on shares of OptiNose from $26.00 to $24.00 and set an “outperform” rating on the stock in a report on Tuesday. Zacks Investment Research cut shares of OptiNose from a “buy” rating to a “hold” rating in a report on Thursday, July 11th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $27.00 price target on shares of OptiNose in a report on Thursday, May 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $22.50.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Further Reading: How is the LIBOR rate calculated?
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.